Adherence to periprocedural antithrombotic treatment recommendations and its prognostic impact in patients with high ischemic and hemorrhagic risk
Rev Esp Cardiol (Engl Ed). 2024 Nov 8:S1885-5857(24)00329-3.
doi: 10.1016/j.rec.2024.09.010.
Online ahead of print.
[Article in
English,
Spanish]
Authors
María Anguita-Gámez
1
, David Vivas
2
, Raquel Ferrandis
3
, María Asunción Esteve-Pastor
4
, Rafael González-Manzanares
5
, Marysol Echeverri
3
, Jesús Igualada
3
, Isabel Egocheaga
6
, Beatriz Nozal-Mateo
7
, Ane Abad-Motos
8
, Elena Figuero
9
, Nuria Bouzó-Molina
10
, Teresa Lozano
11
, Carlos Álvarez-Ortega
12
, Javier Torres
13
, María José Descalzo
14
, Juan Carlos Catalá
15
, Enrique Martín-Rioboo
16
, Alejandra Moliner
17
, Rocío Rodríguez-Contreras
18
, Manuel Carnero-Alcázar
19
, Francisco Marín
4
, Manuel Anguita
5
; REQXAA study researchers
Affiliations
- 1 Instituto Cardiovascular, Hospital Clínico San Carlos, Madrid, Spain. Electronic address: maria.anguita95@gmail.com.
- 2 Instituto Cardiovascular, Hospital Clínico San Carlos, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
- 3 Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- 4 Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, El Palmar, Murcia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
- 5 Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiología, Hospital Universitario Reina Sofía, Instituto Maimónides para la Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, Spain.
- 6 Medicina de Familia, Centro de Salud Isla de Oza, Madrid, Spain.
- 7 Servicio de Anestesiología y Reanimación, Hospital Universitario Infanta Leonor, Madrid, Spain.
- 8 Servicio de Anestesiología y Reanimación, Hospital Universitario Donostia, San Sebastián, Guipúzcoa, Spain.
- 9 Departamento de Especialidades Clínicas Odontológicas, Facultad de Odontología, Universidad Complutense, Madrid, Spain.
- 10 Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Universitario 12 de Octubre, Madrid, Spain.
- 11 Servicio de Cardiología, Hospital General Universitario Doctor Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
- 12 Servicio de Cardiología, Hospital Universitario La Paz, Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain.
- 13 Servicio de Cardiología, Hospital Universitario de Jaén, Jaén, Spain.
- 14 Servicio de Urgencias, Hospital Costa del Sol, Marbella, Málaga, Spain.
- 15 Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital General Universitario de Valencia, Valencia, Spain.
- 16 Medicina de Familia, Unidad de Gestión Clínica Poniente, Instituto Maimónides para la Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, Spain.
- 17 Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Marina Baixa, Villajoyosa, Alicante, Spain.
- 18 Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Universitario Torrecárdenas, Almería, Spain.
- 19 Servicio de Cirugía Cardiaca, Hospital Clínico San Carlos, Madrid, Spain.
Abstract
Introduction and objectives:
To analyze the clinical impact of the inappropriate use of antithrombotic treatment in patients with high ischemic or hemorrhagic risk during the periprocedural/perisurgical period in Spain.
Methods:
Prospective multicenter observational registry of patients receiving antiplatelet and/or anticoagulant therapy who required an intervention. The incidence of 30-day events was compared based on the peri-intervention management of antithrombotic treatment and the patients' risk classification (high vs. moderate-to-low risk). The primary endpoint was a composite of death, cardiovascular ischemic events, or bleeding events classified as BARC 2 or higher.
Results:
A total of 1152 patients were analyzed. Of these, 1.9% had both high ischemic and hemorrhagic risks (A);10.8% had high ischemic risk and low-to-moderate hemorrhagic risk (B); 12% had high hemorrhagic risk and low-to-moderate ischemic risk (C); and 75.3% had both low-to-moderate risks (D). The prevalence of inappropriate treatment was higher in the subgroup with high hemorrhagic risk and low-to-moderate ischemic risk (C) (62.6% vs 40.9% in subgroup A; P<.05; 40.3% in subgroup B; P<.001; and 39.8% in subgroup D; P<.05). The incidence of the composite endpoint was higher in the subgroups with high ischemic and hemorrhagic risks (22.7%) and high ischemic and low-to-moderate hemorrhagic risks (20.9%), compared with 3.6% in subgroup C (P<.05) and 5.7% in subgroup D (P<.001). Among patients with inappropriate treatment, the incidence of the composite endpoint was significantly higher in subgroups with high ischemic and hemorrhagic risks (44.4% vs 7.7%; P=.043) and high ischemic and low-to-moderate hemorrhagic risks (30% vs 14.8%; P=.042).
Conclusions:
The prevalence of inappropriate periprocedural/perisurgical treatment was higher in patients with high hemorrhagic risk and low-to-moderate ischemic risk. The incidence of events was higher in patients with high ischemic risk, with inadequate antithrombotic management being associated with a higher event rate in these groups.
Keywords:
Abordaje perioperatorio; Antiagregantes plaquetarios; Anticoagulantes; Anticoagulants; Antiplatelets; Perioperative management; Prognosis; Pronóstico; Riesgo; Risk.
Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.